Funder: National Institutes of Health
Due Dates: June 3, 2025 | October 1, 2025 | June 3, 2026 | October 1, 2026 (Letter of Intent: 30 days prior to each due date)
Funding Amounts: Up to $500,000 direct costs per year (max 5 years); total program funding ~$3M in FY25 for 2–4 awards (including companion R01)
Summary: Funds high-risk clinical trials to develop advanced in vivo imaging technologies for detailed, non-invasive visualization of the human inner ear in awake patients.
Key Information: Clinical trial is required; only one trial per application; FDA oversight or higher-risk trials only—see eligibility and scope.